Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
BioPharmX financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$83.2 K
FY, 2022
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2014 | FY, 2015 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0K | 100.0K | 73.0K | 57.0K | 453.8K | 886.5K | 83.2K | |||
| Revenue growth, % | -27.0% | -21.9% | ||||||||
| Cost of goods sold | 1.0K | 516.0K | 250.0K | 83.0K | ||||||
| Gross profit | (416.0K) | (177.0K) | (26.0K) | |||||||
| Gross profit margin, % | -416.0% | -242.5% | -45.6% | |||||||
| General and administrative expense | 3.2K | 206.0 | 3.0M | 401.0K | 4.7M | 5.1M | 5.2M | 4.1M | 5.4M | 6.0M |
| Operating expense total | 3.2K | 206.0 | 7.8M | 1.1M | 18.0M | 16.7M | 16.5M | 6.8M | 15.3M | |
| Depreciation and amortization | 1.0K | |||||||||
| EBIT | (59.1K) | (28.0K) | (7.8M) | (1.1M) | (18.4M) | (16.9M) | (16.5M) | (20.2M) | (10.7M) | (19.2M) |
| EBIT margin, % | -114400.0% | -18426.0% | -23117.8% | -28957.9% | -4453.8% | -23125.9% | ||||
| Interest income | 2.0 | 40.0K | 816.7K | 2.4K | ||||||
| Interest expense | 76.0K | |||||||||
| Pre tax profit | (59.1K) | (28.0K) | (18.4M) | (16.6M) | (17.3M) | (15.1M) | (10.7M) | (19.4M) | ||
| Income tax expense | 2.0K | 2.0K | 2.0K | 37.8K | (30.2K) | 7.6K | ||||
| Net Income | (59.1K) | (28.0K) | (7.8M) | (1.1M) | (18.4M) | (16.6M) | (17.3M) | (15.1M) | (10.6M) | (19.4M) |
| EPS | (9.2) |